FDA advisory panel endorsed Grail's multi-cancer blood test in a split vote
- Grail: 2 events in the last 90 days
- Previous: 1 days earlier · FDA advisers are voting on Grail's multicancer blood test as Medicare coverage hangs in the balance
What happened
The committee voted 7-2 that Galleri's benefits outweigh its risks, though members split 6-4 on the question of effectiveness
Summary assembled by rule from the sources below